Last reviewed · How we verify
NCT04745715
Genomic Study in Non-small Cell Lung Cancer Brain Metastasis
trial testing craniectomy in NSCLC Stage IV in 110 participants. Completed in 31 October 2022.
31 October 2020
Quick facts
| Lead sponsor | National Cheng-Kung University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 110 |
| Start date | 1 January 2011 |
| Primary completion | 31 October 2020 |
| Estimated completion | 31 October 2022 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- craniectomy
Conditions studied
- NSCLC Stage IV — all drugs for NSCLC Stage IV →
- Brain Metastases — all drugs for Brain Metastases →
Sponsor
National Cheng-Kung University Hospital
Who can join
Eligibility, any sex, with NSCLC Stage IV or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators collected the data from the investigators' center between January 2011 and October 2020. The study included all non-small cell lung cancer patients with surgically excised brain metastasis. The investigators analysis the correlation of gene mutation and the disease course.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04745715
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of craniectomy
Trials testing the same drug.
- NCT01824706 — Prospective, Multicenter Observational Study Evaluating the Long Term Safety of the Custombone Implant · completed
Other recruiting trials for NSCLC Stage IV
Currently open trials in the same condition.
- NCT07279402 — TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50% · recruiting
- NCT06401824 — Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases · Phase 2 · recruiting
- NCT06532149 — ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · recruiting
- NCT06313541 — Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunothera · Phase 2 · recruiting
- NCT06788366 — AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer · recruiting
Other National Cheng-Kung University Hospital trials
Trials by the same sponsor.
- NCT07525713 — Virtual Reality Mirror Therapy With Focused Object-Directed Attention System · NA · not yet recruiting
- NCT07369271 — Continuous Cervical Erector Spinae Plane Block Versus Interscalene Nerve Block in Shoulder Arthroscopic Surgery · NA · not yet recruiting
- NCT07262411 — Peer-based Recovery Program · NA · not yet recruiting
- NCT07257926 — Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Contr · Phase 4 · not yet recruiting
- NCT07269132 — Applying the ADDIE Model to Develop a Multimedia Program to Enhance Chemotherapy Knowledge and Self-Efficacy Among Inten · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04745715 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cheng-Kung University Hospital
- Last refreshed: 4 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04745715.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing